CareDx together with its subsidiaries, is a medicine company focused on the discovery, development and commercialization of diagnostic solutions for transplant patients and caregivers. Co. provides testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey, and is a provider of genomics-based information for transplant patients. Co.'s commercially available testing services consist of AlloSure® Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients, AlloMap® Heart, a solution for heart transplant patients, AlloSure® Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure® Lung. The CDNA average annual return since 2014 is shown above.
The Average Annual Return on the CDNA average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CDNA average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CDNA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free CDNA Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
